Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Doubling time

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    189 result(s) found for: Doubling time. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-004985-14 Sponsor Protocol Number: SP003 Start Date*: 2012-01-11
    Sponsor Name:Sotio a.s.
    Full Title: Randomized, open-label, parallel-group, multi-centre phase II clinical trial of active cellular immunotherapy DCVAC/PCa in patients with localized prostate cancer after primary radical prostatectomy
    Medical condition: Localized prostate cancer after primary radical prostatectomy
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-003809-26 Sponsor Protocol Number: SP010 Start Date*: 2013-12-04
    Sponsor Name:SOTIO a.s.
    Full Title: Open-label, one-arm, multi-centre phase II clinical trial with second cycle of active cellular immunotherapy DCVAC/PCa in patients with localized prostate cancer after primary radical prostatectomy...
    Medical condition: Localized prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-018187-10 Sponsor Protocol Number: DODO1011 Start Date*: 2010-04-21
    Sponsor Name:Ziekenhuisgroep Twente
    Full Title: Double dose treatment: Corticosteroid injection therapy in arthritis
    Medical condition: To determine whether doubling the dose of triamcinolone injections in the treatment of arthritis in knee joints is more effective, both in number of responding patients and in duration of response ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005848-21 Sponsor Protocol Number: M11-352 Start Date*: 2013-12-18
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy SONAR: Stud...
    Medical condition: Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) BE (Prematurely Ended) GB (Completed) IE (Completed) PT (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) GR (Completed) SK (Prematurely Ended) FI (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000604-14 Sponsor Protocol Number: SPP301CRD15 Start Date*: 2005-08-24
    Sponsor Name:Speedel Pharma Ltd.
    Full Title: A randomised, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist avosentan on time to doubling of serum creatinine, end stage renal di...
    Medical condition: Diabetic Nephropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FI (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) LT (Prematurely Ended) SE (Prematurely Ended) SK (Completed) DE (Prematurely Ended) EE (Prematurely Ended) IT (Prematurely Ended) ES (Ongoing) LV (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-003138-33 Sponsor Protocol Number: SPCG14 Start Date*: 2008-12-12
    Sponsor Name:Scandinavian Prostate Cancer Group (SPCG)
    Full Title: A Randomized, Open Label, Phase III, Multicenter, 2-Arm Study of Androgen deprivation +/- Taxotere (Docetaxel) for Non metastatic Prostate Cancer Patients with a Rising PSA.
    Medical condition: Patients with prostate cancer. The study will include two patient cohorts, which at inclusion has a similar risk for progression of the disease at 5 years, and risk of later prostate cancer death. ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036910 Prostate cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) SE (Completed) DK (Completed) NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-001398-44 Sponsor Protocol Number: PR 2006-04 Start Date*: 2006-06-13
    Sponsor Name:Barts and The London NHS Trust
    Full Title: The use of Peroxisome Proliferator Activator Receptor Agonists in the management of Androgen Independent Prostate Cancer
    Medical condition: The use of Peroxisome Proliferator Activator Receptor Agonists in the management of Androgen Independent Prostate Cancer. Open-labeled, non-randomised clinical trial in patients with androgen indep...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000951-14 Sponsor Protocol Number: RhoVac-002 Start Date*: 2019-08-26
    Sponsor Name:RhoVac ApS
    Full Title: A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men with Biochemical Failure following Curatively Intended Therapy for Localized Prostate Cancer
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed) FI (Completed) SE (Completed) DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2005-002095-15 Sponsor Protocol Number: KRX-101-401 Start Date*: 2005-10-12
    Sponsor Name:Keryx Biopharmaceuticals, Inc.
    Full Title: The Collaborative Study Group Trial: The Effect of Sulodexide in Overt Type 2 Diabetic Nephropathy
    Medical condition: Overt Type 2 Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    8.0 10061835 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) DK (Prematurely Ended) BE (Completed) ES (Completed) PT (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003038-26 Sponsor Protocol Number: ARGX-113-1603 Start Date*: 2017-02-08
    Sponsor Name:Argenx BVBA
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients with Primary Immune Thrombocytopenia, followed by an Op...
    Medical condition: Primary Immune Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004851 10074678 Primary immune thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) CZ (Completed) BE (Completed) DE (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-004848-31 Sponsor Protocol Number: P04039 Start Date*: 2006-01-31
    Sponsor Name:SCHERING-PLOUGH
    Full Title: A Multicenter, Randomized, Parallel-Groups, Double-Blind Placebo Controlled Study Comparing The Efficacy, Safety, And Tolerability Of Administration Of Ezetimibe/Simvastatin tablet 10/20 Mg Versus ...
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    6.1 10020603 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004212-21 Sponsor Protocol Number: AMAG-423-201 Start Date*: 2019-05-24
    Sponsor Name:AMAG Pharmaceuticals, Inc.
    Full Title: A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects with Severe Pree...
    Medical condition: Severe Preeclampsia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10040444 Severe pre-eclampsia LLT
    Population Age: Adults Gender: Female
    Trial protocol: PL (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) BE (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002364-13 Sponsor Protocol Number: M16VIB Start Date*: 2018-01-23
    Sponsor Name:Netherlands Cancer Institute- Antoni van Leeuwenhoek hospital (NKI-AVL)
    Full Title: MoTriColor: A phase II study of vinorelbine in advanced BRAF-like colon cancer
    Medical condition: colon carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001128-38 Sponsor Protocol Number: pVAX/rhPSA -EP 2006 Start Date*: 2008-09-30
    Sponsor Name:Uppsala University Hospital
    Full Title: DNA Vaccine Coding for the Rhesus Prostate Specific Antigen (rhPSA) and Electroporation in Patients with Relapsed Prostate Cancer. A Phase I/II Study
    Medical condition: Patients with relapse of prostate cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003481-14 Sponsor Protocol Number: 3004 Start Date*: 2014-03-07
    Sponsor Name:National Institute of Diabetes and Digestive and Kidney Diseases
    Full Title: Study of allopurinol to prevent GFR loss in type 1 diabetes
    Medical condition: Type 1 diabetes, microalbuminuria or macroalbuminuria and mildly impaired kidney function.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004848 10037827 Raised serum uric acid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000625-37 Sponsor Protocol Number: BED-004 Start Date*: 2015-08-28
    Sponsor Name:Blue Earth Diagnostics Limited
    Full Title: A phase 3, open-label study to assess the clinical utility of fluciclovine (18F) PET/CT in patients with prostate cancer with biochemical recurrence after radical treatment
    Medical condition: Prostate cancer with biochemical recurrence after radical treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004397-99 Sponsor Protocol Number: MBCC28040 Start Date*: 2014-06-17
    Sponsor Name:Instituto Tecnológico PET, S.A.U. (ITP)
    Full Title: A Phase III Clinical Trial to evidence the safety and efficacy of the radio-drug 18f-Fluorocholine (18F-FCH), using Positron Emission Tomography (PET) for the diagnosis of the prostate carcinoma in...
    Medical condition: Prostate Carcinoma in patients with biochemical relapse.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-004297-26 Sponsor Protocol Number: 1632/12 Start Date*: 2012-12-23
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Phase III clinical study of PET-TC with [18f]Fluoroethyilcholine ([18f]Fech) in prostate cancer: assessment of the additional role with respec to conventional imaging techniques
    Medical condition: prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002355-40 Sponsor Protocol Number: SPCG 12 Start Date*: 2005-08-23
    Sponsor Name:Scandinavian prostate cancer group
    Full Title: An open randomized phase III trial of six cycles of docetaxel versus surveillance after radical prostatectomy in prostate cancer patients with high grade pT3 or margin positive pT2
    Medical condition: Men, 18-70 years old, who have had radical prostatectomy due to prostate cancer and with a high grade pT3 or margin positive pT2 tumour may be candidates for the study.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Ongoing) FI (Completed) DK (Completed) IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002165-39 Sponsor Protocol Number: P04887 Start Date*: 2006-11-30
    Sponsor Name:Schering Plough Research Institute, a division of Schering Corporation
    Full Title: Study of the Efficacy and Safety of SCH486757 in Subjects With Chronic Idiopathic Cough
    Medical condition: Chronic Idiopathic Cough
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 02:33:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA